In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis
Open Access
- 1 March 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (3) , 781-785
- https://doi.org/10.1128/aac.45.3.781-785.2001
Abstract
The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were >128 mg/liter. For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter. The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h. Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs. Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment ofP. aeruginosa infections in cystic fibrosis patients.Keywords
This publication has 14 references indexed in Scilit:
- Peptide Antibiotics1999
- In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibioticsClinical Microbiology & Infection, 1999
- Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosisThorax, 1997
- The postantibiotic effect of imipenem: relationship with drug concentration, duration of exposure, and MICAntimicrobial Agents and Chemotherapy, 1997
- A reassessment of the in-vitro activity of colistin sulphomethate sodiumJournal of Antimicrobial Chemotherapy, 1997
- [Pulmonary deposition of colistin aerosols in cystic fibrosis. Comparison of an ultrasonic nebulizer and a pneumatic nebulizer].1996
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993
- Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis.BMJ, 1968
- POLYMYXIN B AND COLISTIN - IN VITRO ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA1965
- Intravenous Administration of Sodium ColistimethateJAMA, 1964